CAMP4 Therapeutics announced the grant of 8,000 non-qualified stock options to a newly hired employee on February 16, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The options carry an exercise price of $3.85 per share and feature a standard four-year vesting schedule with a ten-year expiration term.
The inducement grant represents a routine equity compensation arrangement used by the company to attract talent to its operations. CAMP4, which focuses on RNA-targeting therapeutics, utilizes such awards as part of its broader compensation strategy to support its pipeline development and organizational expansion.
Under Nasdaq regulations, companies may issue equity awards to newly hired employees outside of shareholder-approved plans when such grants serve as material inducement to employment. The grant structure aligns with typical market practices for equity-based compensation in the biopharmaceutical sector.